ERBB2 and congenital rubella syndrome: FT819 (anti‐CD19 CAR‐T cells with a TRAC‐integrated CAR) showed no dose‐limiting toxicity, GVHD or severe CRS in a phase I trial, with responses in four of 15 patients, FT825/ONO‐8250 (anti‐HER2, seven edits) seeks to improve solid tumour targeting.